References
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2021 [cited 2023 Jan 2];71(3):209–249. Available from: https://pubmed.ncbi.nlm.nih.gov/33538338/
- Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer [Internet]. 2019 [cited 2023 Mar 23]; 7(1). Available from: https://pubmed.ncbi.nlm.nih.gov/31307547/
- Gormley M, Creaney G, Schache A, et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. B DJ. 2022 233:9 [Internet]. 2022 [cited 2023 Jan 2];233:780–786. . Available from: https://www.nature.com/articles/s41415-022-5166-x
- Nenclares P, Gunn L, Soliman H, et al. On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. J Immunother Cancer. 2021;9(6):e002718. doi: 10.1136/jitc-2021-002718
- Yasui K, Kondou R, Miyata H, et al. Immunological and genetic characterization of patients with head and neck cancer who developed recurrence. Anticancer Res [Internet]. 2022 [cited 2022 Dec 15];42(9):4417–4428. Available from: https://pubmed.ncbi.nlm.nih.gov/36039416/
- Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol [Internet]. 2002 [cited 2023 Jan 2];3(11):991–998. Available from: https://pubmed.ncbi.nlm.nih.gov/12407406/
- Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight [Internet] 2016 [cited 2022 Oct 19];1(17). Available from: https://pubmed.ncbi.nlm.nih.gov/27777979/
- Zhou C, Diao P, Wu Y, et al. Development and validation of a seven-immune-feature-based prognostic score for oral squamous cell carcinoma after curative resection. Int J Cancer. 2020;146(4):1152–1163. doi: 10.1002/ijc.32571
- Schmidl B, Siegl M, Boxberg M, et al. NOTCH1 intracellular domain and the tumor microenvironment as prognostic markers in HNSCC. Cancers (Basel). [Internet]. 2022. [cited 2023 Mar 22]. 14(4);1080. Available from: https://pubmed.ncbi.nlm.nih.gov/35205828/
- Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials [Internet]. 2007 [cited 2022 Dec 20]; 8(1). Available from: https://pubmed.ncbi.nlm.nih.gov/17555582/
- Succaria F, Kvistborg P, Stein JE, et al. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Cancer Immunol Immunother [Internet]. 2021;70(5):1227–1237. [cited 2022 Oct 19]. Available from: https://pubmed.ncbi.nlm.nih.gov/33125511/
- Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) [Internet]. [cited 2023 Jan 2]. 2020;12:738. Available from. 3. /pmc/articles/PMC7140028/
- Rao S, Gharib K, Han A. Cancer immunosurveillance by T cells. Int Rev Cell Mol Biol [Internet]. 2019 [cited 2022 Dec 13];342:149–173. Available from: https://pubmed.ncbi.nlm.nih.gov/30635090/
- Lechner A, Schlößer H, Rothschild SI, et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget Internet. 2017;8(27):44418–44433. [cited 2023 Jan 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/28574843/
- Lechner A, Schlößer HA, Thelen M, et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma. Oncoimmunology [Internet]. 2019;8(3):1535293. [cited 2022 Oct 12]. Available from: https://pubmed.ncbi.nlm.nih.gov/30723574/
- Wieland A, Patel MR, Cardenas MA, et al. Defining HPV-specific B cell responses in patients with head and neck cancer. Nature [Internet]. 2021;597(7875):274–278. [cited 2022 Dec 15]. Available from: https://pubmed.ncbi.nlm.nih.gov/33208941/
- Mito I, Takahashi H, Kawabata-Iwakawa R, et al. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. Sci Rep [Internet]. 2021. [cited 2022 Dec 15];11:16134. Available from: /pmc/articles/PMC8352955/.
- Chen SMY, Krinsky AL, Woolaver RA, et al. Tumor immune microenvironment in head and neck cancers. Mol Carcinog. 2020;59(7):766–774. doi: 10.1002/mc.23162
- Gao L, Zhang W, Zhong WQ, et al. Tumor associated macrophages induce epithelial to mesenchymal transition via the EGFR/ERK1/2 pathway in head and neck squamous cell carcinoma. Oncol Rep [Internet]. 2018 [cited 2022 Oct 12];40:2558–2572. Available from: https://pubmed.ncbi.nlm.nih.gov/30132555/
- Charap AJ, Enokida T, Brody R, et al. Landscape of natural killer cell activity in head and neck squamous cell carcinoma. J Immunother Cancer [Internet]. 2020;8(2):e001523. [cited 2022 Oct 22]. Available from: https://pubmed.ncbi.nlm.nih.gov/33428584/
- Nguyen N, Bellile E, Thomas D, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38(7):1074–1084. doi: 10.1002/hed.24406
- Chen X, Yan B, Lou H, et al. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis. Mol Immunol [Internet]. 2018 [cited 2022 Oct 12];96:28–36. Available from: https://pubmed.ncbi.nlm.nih.gov/29477933/
- Jung AC, Guihard S, Krugell S, et al. CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. Int J Cancer [Internet]. 2013 [cited 2022 Dec 13];132(2):E26–E36. Available from: https://pubmed.ncbi.nlm.nih.gov/22890882/
- Borsetto D, Tomasoni M, Payne K, et al. Prognostic significance of CD4+ and CD8+ tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: a meta-analysis. Cancers (Basel) [Internet]. 2021. [cited 2022 Oct 12]. 13(4);1–15. Available from http://www.ncbi.nlm.nih.gov/pubmed/33668519
- Balermpas P, Michel Y, Wagenblast J, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014;110(2):501–509. doi: 10.1038/bjc.2013.640
- Berele BA, Cai Y, Yang G. Prognostic value of tumor infiltrating lymphocytes in nasopharyngeal carcinoma patients: meta-analysis. Technol Cancer Res Treat [Internet]. 2021 [cited 2022 Dec 18];20:153303382110342. Available from: https://pubmed.ncbi.nlm.nih.gov/34323154/
- Rodrigo JP, Sánchez-Canteli M, López F, et al. Tumor-infiltrating lymphocytes in the tumor microenvironment of laryngeal squamous cell carcinoma: systematic review and meta-analysis. Biomedicines [Internet]. 2021;9(5):486. [cited 2022 Oct 12]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33925205
- Almangush A, Leivo I, Mäkitie AA. Overall assessment of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: time to take notice. Acta Otolaryngol. 2020;140:246–248. doi: 10.1080/00016489.2020.1720284
- Koukourakis IM, Gkegka AG, Xanthopoulou E, et al. Prognostic and predictive relevance of tumor-infiltrating lymphocytes in squamous cell head–neck Cancer patients treated with radical radiotherapy/Chemo-radiotherapy. Current Oncology [Internet]. 2022. [cited 2022 Dec 15];29:4274–4284. Available from: https://pubmed.ncbi.nlm.nih.gov/35735451/.
- Nicolay NH, Ruhle A, Wiedenmann N, et al. Lymphocyte infiltration determines the hypoxia-dependent response to definitive chemoradiation in head-and-neck cancer: results from a prospective imaging trial. J Nucl Med [Internet]. 2021;62(4):471–478. [cited 2023 Mar 21]. Available from: https://pubmed.ncbi.nlm.nih.gov/32859699/
- de Ruiter EJ, de Roest RH, Brakenhoff RH, et al. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors. Cancer Immunol Immunother. 2020;69:581–591. doi: 10.1007/s00262-020-02481-3
- de Meulenaere A, Vermassen T, Aspeslagh S, et al. Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes. Pathology. 2017;49(4):397–404. doi: 10.1016/j.pathol.2017.02.002
- Zhang D, Tang D, Heng Y, et al. Prognostic impact of tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma patients. Laryngoscope. 2021;131(4):E1249–E1255. doi: 10.1002/lary.29196
- de Ruiter EJ, Ooft ML, Devriese LA, et al. The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Oncoimmunology. 2017;6:6. doi: 10.1080/2162402X.2017.1356148
- Kulasinghe A, Taheri T, O’Byrne K, et al. Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients. Front Oncol [Internet]. 2021 [cited 2022 Oct 23];10. Available from: https://pubmed.ncbi.nlm.nih.gov/33542903/
- de Keukeleire SJ, Vermassen T, Hilgert E, et al. Immuno-oncological biomarkers for squamous cell cancer of the head and neck: current state of the art and future perspectives. Cancers (Basel). 2021;13:1714. doi: 10.3390/cancers13071714
- Bron L, Jandus C, Andrejevic-Blant S, et al. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer. 2013;132(3):E85–E93. doi: 10.1002/ijc.27728
- Ljokjel B, Haave H, Lybak S, et al. Tumor infiltration levels of CD3, Foxp3 (+) lymphocytes and CD68 macrophages at diagnosis predict 5-year disease-specific survival in patients with oropharynx squamous cell carcinoma. Cancers (Basel) [Internet]. 2022;14(6):1508. [cited 2022 Dec 17]. Available from: https://pubmed.ncbi.nlm.nih.gov/35326661/
- Shang B, Liu Y, Jiang SJ, et al. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1): doi: 10.1038/srep15179
- Zhang S, Wang B, Ma F, et al. Characteristics of B lymphocyte infiltration in HPV+ head and neck squamous cell carcinoma. Cancer Sci [Internet]. 2021. [cited 2022 Dec 16];112:1402–1416. Available from: https://pubmed.ncbi.nlm.nih.gov/33529452/.
- Kim SS, Shen S, Miyauchi S, et al. B cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade. Clin Cancer Res [Internet]. 2020;26(13):3345–3359. [cited 2022 Dec 15]. Available from: https://pubmed.ncbi.nlm.nih.gov/32193227/
- Qureshi HA, Zhu X, Yang GH, et al. Impact of HPV status on immune responses in head and neck squamous cell carcinoma. Oral Oncol [Internet]. 2022 [cited 2022 Dec 17];127:105774. Available from: https://pubmed.ncbi.nlm.nih.gov/35219073/
- Seminerio I, Kindt N, Descamps G, et al. High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus. Oncotarget. 2018;9(13):11046–11059. doi: 10.18632/oncotarget.24306
- Weber M, Büttner-Herold M, Hyckel P, et al. Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages - an immunohistochemical analysis. J Craniomaxillofac Surg. 2014;42:1087–1094. doi: 10.1016/j.jcms.2014.01.035
- Hori Y, Kubota A, Yokose T, et al. Prognostic role of tumor-infiltrating lymphocytes and tumor budding in early oral tongue carcinoma. Laryngoscope. 2021;131(11):2512–2518. doi: 10.1002/lary.29589
- Balermpas P, Rödel F, Liberz R, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer [Internet]. 2014;111(8):1509–1518. [cited 2022 Oct 12]. Available from: https://pubmed.ncbi.nlm.nih.gov/25093488/
- Wondergem NE, Nauta IH, Muijlwijk T, et al. The immune microenvironment in head and neck squamous cell carcinoma: on subsets and subsites. Curr Oncol Rep. 2020;22(8):22. doi: 10.1007/s11912-020-00938-3
- Conroy MJ, Kennedy SA, Doyle SL, et al. A study of the immune infiltrate and patient outcomes in esophageal cancer. Carcinogenesis [Internet]. 2021;42(3):395–404. [cited 2022 Oct 17]. Available from: https://pubmed.ncbi.nlm.nih.gov/32940666/
- Balermpas P, Rödel F, Weiss C, et al. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology. 2014;3(1):3. doi: 10.4161/onci.27403
- Spanier G, Ugele I, Nieberle F, et al. The predictive power of CD3+ T cell infiltration of oral squamous cell tumors is limited to non-diabetic patients. Cancer Lett [Internet]. 2021 [cited 2023 Aug 1];499:209–219. Available from: https://pubmed.ncbi.nlm.nih.gov/33276040/
- Suzuki H, Kawasaki Y, Miura M, et al. Tumor infiltrating lymphocytes are prognostic factors and can be markers of sensitivity to chemoradiotherapy in head and neck squamous cell carcinoma. Asian Pac J Cancer Prev [Internet]. 2022;23(4):1271–1278. [cited 2022 Dec 16]. Available from: https://pubmed.ncbi.nlm.nih.gov/35485685/
- Fiedler M, Weber F, Hautmann MG, et al. Infiltrating immune cells are associated with radiosensitivity and favorable survival in head and neck cancer treated with definitive radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol [Internet]. 2020;129(6):612–620. [cited 2022 Dec 16]. Available from: https://pubmed.ncbi.nlm.nih.gov/32409191/
- Distel LV, Fickenscher R, Dietel K, et al. Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol [Internet]. 2009. [cited 2022 Dec 13];45:e167–e174. Available from: https://pubmed.ncbi.nlm.nih.gov/19576838/.
- Liu Z, McMichael EL, Shayan G, et al. Novel effector phenotype of tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck Cancer patients. Clin Cancer Res [Internet]. 2018;24(18):4529–4538. [cited 2022 Dec 17]. Available from: https://pubmed.ncbi.nlm.nih.gov/29712685/
- de Meulenaere A, Vermassen T, Aspeslagh S, et al. Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer. Oncotarget. 2017;8(46):80443–80452. doi: 10.18632/oncotarget.19045
- Tsujikawa T, Kumar S, Borkar RN, et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep [Internet]. 2017;19(1):203–217. [cited 2022 Dec 15]. Available from: https://pubmed.ncbi.nlm.nih.gov/28380359/
- Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med [Internet]. 2012 [cited 2023 Mar 22]; 10(1). Available from: https://pubmed.ncbi.nlm.nih.gov/23034130/
- Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol. 2014;232:199–209. doi: 10.1002/path.4287
- Zhang XM, Song LJ, Shen J, et al. Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma. Hum Pathol. 2018;82:104–112. doi: 10.1016/j.humpath.2018.07.012
- Spector ME, Bellile E, Amlani L, et al. Prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma. JAMA Otolaryngology–Head & Neck Surg. 2019;145(11):1012–1019. doi: 10.1001/jamaoto.2019.2427
- Shaban M, Raza SEA, Hassan M, et al. A digital score of tumour-associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma. J Pathol. 2022;256(2):174–185. doi: 10.1002/path.5819
- Furgiuele S, Descamps G, Lechien JR, et al. Immunoscore combining CD8, FoxP3, and CD68-positive cells density and distribution predicts the prognosis of head and neck Cancer patients. Cells. 2022;11(13):11. doi: 10.3390/cells11132050
- Duan J, Xie Y, Qu L, et al. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy 11 Medical and health Sciences 1107 Immunology. J Immunother Cancer. 2018;6(1):6. doi: 10.1186/s40425-018-0418-7